AstraZeneca (AZN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

AZN AstraZeneca

Watchlist

65.520
-0.050-0.08%

Close Dec 31 16:00 ET

65.520
0.0000.00%

Post 20:01 ET

203.15BMarket Cap31.58P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Takeda-backed Ascentage Pharma Files for $100M IPO
Seeking AlphaDec 30, 2024 16:22 ET
AstraZeneca (AZN.US) has a potentially significant ADC approved for the treatment of breast cancer.
The antibody-drug conjugate (ADC) Datroway (datopotamab deruxtecan), jointly developed by Daiichi Sankyo and AstraZeneca (AZN.US), has been approved in Japan.
Zhitong FinanceDec 30, 2024 08:07 ET
Morgan Stanley: Personalized cancer vaccines and ADCs will become the main catalysts in the oncology treatment Industry by 2025.
Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADCs) will become one of the major innovations in cancer biotechnology next year.
Zhitong FinanceDec 30, 2024 03:51 ET
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?
Yahoo FinanceDec 29, 2024 04:14 ET
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Seeking AlphaDec 28, 2024 10:31 ET
Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know
Yahoo FinanceDec 27, 2024 18:15 ET

Comments

10xStockPicks

Dec 29, 2024 17:56

Roaring Kitty New Years Eve Party, New Investment Idea For 2025

It is rumored Keith Gill will make new investments in 2025 potentially in the health care sector, based on the new Trump administration & RFK looking out for the health of Americans. Rumor is Keith is attending a New Years Eve party with a friend who's father take a statin alternative drug called NEXLIZET made by $Esperion Therapeutics (ESPR.US)$
This information comes from a friend of CNBC Jim Cramer who is also statin intolerant an...

Meltyy

Dec 17, 2024 01:56

📌 1 PDUFA this weekand 6 more upcoming this month! 🚀

🔔 This Week’s PDUFA:
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...